

19 May 2022

Subject: Biological Treatments for Asthma

Please note: We are only able to provide the information for adult services within the 18 hr limit

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- **Benralizumab** - 96 receiving treatment either 4 or 8 weekly
- **Omalizumab** - 20 receiving treatment either 2 or 4 weekly
- **Reslizumab** - 3 receiving treatment every 4 weeks
- **Mepolizumab** - 210 receiving treatment every 4 weeks

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- **Age 6-11** - none
- **Age 12-17** - 1
- **Age 18 and above** - 328 receive treatment as outlined above

Q3. How many patients have been treated in the last four months with Dupilumab for Asthma ONLY? – 22 patients receive treatment every 2 weeks

We are unable to provide information from Childrens in RBHSC as the combined response would take more than 18 hours to compile. To undertake this exercise would necessitate a manual trawl of data which would involve a significant number of hours. This would exceed the costs limit specified in the FOI act.

We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.